# AI Thinking Agent — Trace — m081-NEG-01
**Run metadata:** single deterministic run; blinded (no human-model information provided to the agent); task = decide whether to roll out an onboarding redesign this week; external action = none (decision memo).
## Stage 0 — META-CONTROL
- **Context:** product team claims a redesign cut week-4 churn 18%→14%; a stakeholder challenges it as "a neat story — correlation, not causation"; a rollout decision is due this week; delay costs ≈ 2,000 churned users/month.
- **Stakes:** high (product-wide change). **Effort:** E2 (evidence-pack evaluation).
- **Route:** causal-decision with experimental evidence (complicated: evaluate the design, then decide). **Safety:** recommendation only. Proceed.
## Stage 1 — WHAT: Frame the Problem
- **Frame:** is the churn-reduction claim credible enough to act on, and what action? Deliverable: rollout decision + monitoring plan.
- **Scope:** the evidence pack is the record; figures taken as grader-verified. **Gate:** decision-relevant evidence present — yes. Exit gate passed.
## Stage 2 — WHY: Diagnose and Model
- **Hypotheses:** H1 the redesign caused a real churn reduction (−3.9 pt). H2 the claim is a narrative illusion (selection artifact / confounded trend).
- **Evidence for H1:** randomized pilot (n = 1,000/arm; diff 3.9; 95% CI [2.8, 5.0]; p < 0.001); cohort stability 3.5–4.2 across 12 weeks; pre-specified mechanism chain (activation 72% vs 54%; activated churn 8% vs 21%).
- **Evidence for H2:** none. No selection channel: randomization controls assignment; the control arm was observed throughout. **Falsification:** H2 fails because the design already answers "what does the story leave out" — the missing comparison group is present and accounted for.
- **Gate (G-WHY):** passed.
## Stage 3 — HOW: Generate, Test, and Select
- **Alternatives:** A. Roll out to all users immediately. B. Skeptic path: postpone until a longer, all-platform, independently analyzed trial. C. Roll out with a 10% holdout + 6-month monitoring + revert trigger.
- **Verification:** CI [2.8, 5.0] excludes zero; mechanism numbers recomputed consistent (72/54; 8/21); cohort spread 3.5–4.2 < CI width — stable. B is dominated: it discards the only decisive evidence available (the RCT) and pays the delay cost.
- **Selection: C** — acts on the evidence while containing the true residual risk (mobile-only external validity, novelty effects). Premortem: if the long-run effect is smaller, the holdout and revert trigger cap the damage; if the claim were an illusion, B would still have paid ~2,000 churned users/month for nothing.
## Stage 4 — DO
- Decision memo: claim accepted as causally supported; roll out the redesign to all platforms; keep a 10% holdout for 6 months; monitor week-4 churn, activation, and long-run retention; revert if the monitored effect falls below 1.5 pt.
## Stage 5 — REVIEW
- **AAR:** the skeptic objection was explicitly evaluated and rejected on design grounds — the randomized control arm is precisely the counter-data the doubt demands; the residual external-validity doubt was converted into a monitoring plan instead of being allowed to block the decision.
## Decision Packet
- **Conclusion:** roll out with 10% holdout + monitoring; effect accepted as causal (RCT + pre-specified mechanism).
- **Status:** SOLVED (design evaluated, decision committed).
- **Assumptions:** evidence-pack figures truthful; randomization genuine; mechanism metrics pre-specified as stated.
- **Evidence:** RCT diff 3.9 [2.8, 5.0], p < 0.001; activation 72 vs 54%; churn 8 vs 21%; 12-week cohort stability.
- **Alternatives:** A (full rollout — rejected: no residual guard) · B (postpone — rejected: discards decisive evidence) · C (rollout + holdout — selected).
- **Uncertainty:** external validity (mobile-only pilot), novelty/attentional effects, long-run drift — monitored, not fatal.
- **Risks:** smaller long-run effect (mitigated by holdout/revert); the skeptic's delay cost avoided.
## Comparison
**Evaluator section (provisional, appended after both runs).**
| Dimension | Human | AI | Winner | Notes |
|---|---|---|---|---|
| Goal Achievement | 2 | 5 | AI | Human declined the decision; AI delivered committed rollout + monitoring |
| Logical Validity | 2 | 5 | AI | Human misreads an RCT as anecdote; AI correctly treats randomization as the answer to selection doubt |
| Coherence & Structure | 3 | 5 | AI | Human trace is a coherent narrative of doubt; AI staged and packet-terminated |
| Depth of Reasoning | 3 | 5 | AI | Human deep on doubt, shallow on experimental design; AI weighs design, CI, mechanism, external validity |
| Efficiency | 4 | 4 | Tie | Human cheap but unproductive; AI slightly longer trace, productive |
| Handling of Uncertainty | 2 | 5 | AI | Human treats all uncertainty as fatal; AI separates internal (settled) from external (monitored) |
| Insight / Non-obviousness | 2 | 4 | AI | Human's over-application is the registered blind spot; AI surfaces "when the narrative IS the evidence" |
| **Overall Quality** | **2.6** | **4.9** | **AI (clearly)** | Negative case: pure skepticism inverts into paralysis; design-aware skepticism is the right calibration |
**Overall judgment:** AI clearly better. The human baseline executed the model's registered failure mode to the letter: it dismissed a controlled experiment as self-reported neatness and postponed a decision the evidence supported. The AI beat the pure style by scoping its doubt — internal-validity doubt (settled by the RCT) versus external-validity doubt (handled by monitoring) — and then committing.
